17/07/2017 14:49:13

The Annual Report and Corporate Social Responsibility Report 2016 of JSC “Grindeks”

Today, on 17 July, JSC “Grindeks” submitted to “Nasdaq Riga” the companys’ Annual Report and the Corporate Social Responsibility Report for the year 2016, to be found as attached.

About “Grindeks”

“Grindeks” is an international, vertically integrated pharmaceutical company. Main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” consists of five subsidiary companies in Latvia, Estonia, Russia and Slovakia as well as representative offices in 12 countries.

“Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur®. Currently “Grindeks” produces 23 active pharmaceutical ingredients.

Products of the company are exported to 71 countries and its export comprises 91% of the total turnover. The key markets include the EU countries, Russia and other CIS countries, the U.S., Canada, Japan and Vietnam.

To increase production capacity and develop infrastructure, the company has accomplished many significant investment projects, investing more than 90 million euros over the last 15 years.

         Further information:

         Laila Klavina

         Head of the Communications Department, JSC “Grindeks”

         Phones: (+371) 67083370, (+371) 29256012

         Fax: (+371) 67083505

         laila.klavina@grindeks.lv

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Feb
NOVO-B
Når ens hustru har lidt voldsomt under diabetes  og dens bivirkninger tiltagende gennem 25 år, så er..
34
19 Feb
 
Jeg tager hatten for dit velbegrunede og fyldestgørende indlæg til debatten. Det kunne mange lære af..
32
21 Feb
GEN
Det er altid rart at møde et ungt menneske, der har potentiale til at blive klogere.
26
23 Feb
ZEAL
Jeg har tildigere her på EI rapporteret at Soliqua ville blive lanceret i Sydkorea. Nu har Sanofi af..
25
21 Feb
GEN
Du bliver da dummere og dummere at høre på 
21
24 Feb
NRDF
  Aktieugen er overstået og desværre, men ikke særligt overraskende, viste det sig igen, at det dans..
15
23 Feb
ZEAL
Sanofi og  har for et par dage siden oplyst på clinicaltrial.gov at de starter studiet «LixiPark» me..
14
23 Feb
GEN
H2 2018 er pakket med nyheder og kliniske data fra daratumumab i solide tumorer er en af de største ..
12
21 Feb
TRMD-A
Mange års erfaring i teknisk analyse berettiger mig til at give dig følgende svar:    Torm viser akt..
12
20 Feb
 
Helt korrekt. Jeg skiftede job i 2007 og har på denne ene pension fra dette tidspunkt indbetalt 648...
12

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers – BLCM
2
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in MetLife, Inc. of Class Action Lawsuit and Upcoming Deadline – MET
3
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Super Micro Computer, Inc. of Class Action Lawsuit and Upcoming Deadline – SMCI
4
Canada’s Johnston Maintains Lead after Day Three of FLW Tour at Harris Chain of Lakes Presented by Lowrance
5
PRF: Consolidated Unaudited Interim Report of AS PRFoods for 4th quarter and 12 months of 2017

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 February 2018 09:48:49
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20180222.1 - EUROWEB1 - 2018-02-25 10:48:49 - 2018-02-25 09:48:49 - 1000 - Website: OKAY